Accessibility Menu
RxSight logo

RxSight(NASDAQ) RXST

Market Cap$259.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-61%
5 Year-48%
1 Year-28%
1 Month+16%
Premium Feature
Moneyball Superscore
56/100
$6.28
+3.04%
+0.19Today
After hours$6.26-$0.01 (-0.24%)
RxSight last closing stock price
MetricPriceDate
Last closeUSD 6.252026-08-21
RxSight stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.29%USD 6.892026-08-14
1 month+15.96%USD 5.392026-07-22
3 month+2.71%USD 6.092026-05-22
Year to date-40.02%USD 10.422025-12-31
1 year-28.41%USD 8.732025-08-21
3 year-79.13%USD 29.952023-08-22
5 year-48%USD 12.022021-08-20
Since inception-60.94%USD 16.002021-07-30

RxSight Financials at a Glance

Market Cap

$259.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$127.58M

Net Income (TTM)

-$46.95M

EPS (TTM)

-$1.14

P/E Ratio

-5.49

Dividend

$0.00

Beta (Volatility)

1.34 (Average)

Price

$6.28

Volume

618

Open

$6.10

Previous Close

$6.25

Daily Range

$6.00 - $6.31

52-Week Range

$4.48 - $13.22

Estimated Earnings Date

Nov 4, 2026

RXST News

Foolcom-Featured.png

RxSight (RXST) Q2 Loss Beats Estimates

Motley Fool Markets TeamAug 7, 2025

RXST: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RxSight

RxSight, Inc. makes adjustable lenses for cataract surgery. These lenses help doctors improve vision after a surgical procedure. Technology lets patients customize their sight with a doctor's help.

Tools for Better Sight

  • Light Adjustable Lens: Photosensitive silicone lenses designed for implantation during cataract surgery to replace the natural lens.
  • Light Delivery Device: In-office instrument that generates specific ultraviolet light patterns to modify the implanted lens power.
  • Accessories and Support: Practice development tools and maintenance services for clinical users and surgery centers.

Recent Strategic Moves

  • Partnered with Alcon Pharmaceuticals on June 30, 2026, to develop light-adjustable versions of specific vision lenses.
  • Announced a pipeline of next-generation lenses and astigmatism-correcting products on July 6, 2026.
  • Appointed a new President and Chief Executive Officer on July 13, 2026, to succeed the previous leadership.
  • Adopted an inducement equity incentive plan in July 2026 to facilitate the hiring of new employees.

Why the Technology Is Unique

The company uses a razor and razor blade business model to drive recurring lens sales through its installed base of devices. This approach allows doctors to refine vision after surgery instead of relying on preoperative guesswork and predictive formulas.

Key Financial Numbers

  • Total revenue was $33.7 million for the three months ended June 30, 2026, up 0.3% year over year.
  • Product sales reached $27.2 million for the three months ended June 30, 2026, down 19.0% year over year.
  • License and collaboration revenue was $6.5 million in the three-month period ended June 30, 2026.
  • Net loss reached $28.0 million for the six-month period ended June 30, 2026, compared to $20.0 million in the same period in 2025.
  • Cash, cash equivalents, and short-term investments totaled $208.8 million as of June 30, 2026.

Looking at the Big Picture

RxSight has transitioned into a commercial-stage company focused on post-surgical vision customization and medical device innovation. Its collaboration with industry leaders and expanded lens pipeline demonstrate a commitment to refining surgical outcomes for cataract patients.

AI Generated • Aug 6, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

461

CEO

Ronald M. Kurtz, MD

Website

rxsight.com

Headquarters

Aliso Viejo, CA 92656, US

RXST Financials

Key Financial Metrics (TTM)

Gross Margin

77.50%

Operating Margin

-43.20%

Net Income Margin

-36.80%

Return on Equity

-17.35%

Return on Capital

-16.81%

Return on Assets

-13.31%

Earnings Yield

-18.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$259.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

41.59M

Volume

618

Avg. Volume

1.15M

Financials (TTM)

Gross Profit

$98.87M

Operating Income

-$55.11M

EBITDA

-$43.29M

Operating Cash Flow

-$22.73M

Capital Expenditure

-$4.43M

Free Cash Flow

-$27.17M

Cash & ST Invst.

$208.80M

Total Debt

$10.58M

RxSight Performance Analysis

RxSight annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 49,005,000116.9%
20232023-12-31USD 89,077,00081.8%
20242024-12-31USD 139,927,00057.1%
20252025-12-31USD 134,479,000-3.9%
RxSight sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-9.8%
Q42025-12-317.5%
Q12026-03-31-5.3%
Q22026-06-309.2%
RxSight annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.4135.6%
20232023-12-31USD -1.41-41.5%
20242024-12-31USD -0.71-49.9%
20252025-12-31USD -0.9535.0%
RxSight sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3017.2%
Q42025-12-318.3%
Q12026-03-31-72.7%
Q22026-06-3023.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$33.74M

+0.3%

Gross Profit

$25.89M

+2.8%

Gross Margin

76.72%

N/A

Market Cap

$259.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$563.90K

N/A

Employees

461

N/A

Net Income

-$12.10M

-2.6%

EBITDA

-$11.01M

-0.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$208.80M

-8.2%

Total Debt

$10.58M

-9.7%

Accounts Receivable

$78.52M

+179.8%

Inventory

$37.12M

+48.1%

Long Term Debt

$8.92M

-16.0%

Short Term Debt

$1.66M

+51.1%

Return on Assets

-13.31%

N/A

Return on Invested Capital

-20.24%

N/A

Free Cash Flow

-$11.49M

-94.4%

Operating Cash Flow

-$9.54M

-118.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TMCITreace Medical Concepts, Inc.
$4.34-2.69%
SMLRSemler Scientific, Inc.
$20.33-4.87%
DMACDiaMedica Therapeutics Inc.
$6.52+0.00%
NPCENeuroPace, Inc.
$14.03+0.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$120.60-0.01%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.03+0.02%
IBITiShares Bitcoin Trust
$43.68+0.06%
MSTRStrategy
$119.25+0.06%

Questions About RXST

What is the current price of RxSight?

RxSight is trading at $6.25 per share.

What is the 52-week range for RxSight?

Over the past 52 weeks, RxSight has traded between $4.48 and $13.22.

How much debt does RxSight have?

As of the most recent reporting period, RxSight reported total debt of $10.58M.

How much cash does RxSight have on hand?

RxSight reported $13.35M in cash and cash equivalents in its most recent financial results.

What is RxSight’s dividend yield?

RxSight does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services